Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2154142

Treatment Algorithms: Rectal Cancer – Inclusion of Chemoradiation can Influence Treatment and Prescribing Trends

Description:
This report provides analysis of current treatment dynamics of rectal cancer. Based on Datamonitor’s survey of 127 oncologists and cancer treaters the report assesses treatment type, prescribing influences, and patient numbers across disease stages.

The rectal cancer pipeline has grown as pharmaceutical companies are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral part of treatment, but with key brands expected to come off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve.

Scope

- Disease overview assessing, etiology, risk factors, screening procedures, and patient segmentation
- In-depth analysis of most common treatment types according to stage at diagnosis and patient characteristics
- Analysis of physician prescribing trends in the seven major markets across all stages of disease
- Analysis of possible future treatment trends with regard to targeted therapies and companion diagnostics

Highlights

- The standard of care for Stage I–III rectal cancer is based around surgical resection. The use of radiotherapy-based treatment increases with stage, with 66% of Stage IIIc patients treated with surgery and chemoradiation. However, Japanese physicians interviewed indicated that they did not use chemoradiation.

- First-line treatment of metastatic rectal cancer is based on chemotherapy. Datamonitor’s survey indicated that 85% of Stage IV patients receive treatment containing chemotherapy, and 34% receive chemotherapy without any additional therapy. The use of chemoradiation in the first-line setting can impact treatment choices in the second-line.

- Datamonitor’s survey indicated that the use of targeted therapies in the first- and second-line settings will increase. Increasing pressure to demonstrate cost-effectiveness of drugs and anticipated approval of new targeted therapies means the use of companion diagnostics will play an increasingly important role in the treatment of rectal cancer.

Reasons to Purchase

- Gain insight into the treatment strategies and prescribing trends of 127 physicians treating rectal cancer across the seven major markets
- Excel deliverable contains extensive treatment trees for each disease stage and country, including percentages and patient numbers
- Assess rectal cancer market potential by identifying where treatment options are not fulfilling patient needs and how physicians select drugs
 
Contents:
OVERVIEW
- Catalyst
- Summary

EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor key findings
- Related reports

DISEASE DEFINITION AND DIAGNOSIS
- Disease definition
- - Colorectal cancer is the third most common tumor type and cause of cancer-related death in both men and women
- - The only differentiator between colon cancer and rectal cancer is primary tumor location

- Etiology
- - Adenomas are precursors to the majority of colorectal cancer cases
- - Inherited and environmental factors are instrumental in the etiology of colorectal cancer

- Symptoms
- - Change in bowel habits is the principle symptom of colorectal cancer

- Prognosis
- - Survival rates for colorectal cancer patients still lag behind those in other high-incidence indications

- Presentation and diagnosis
- - Screening reduces colorectal cancer incidence and mortality

- Influences on diagnosis and treatment rates
- - Screen for Life: National Colorectal Cancer Action Campaign
- - In 2012 the ""Be clear on cancer"" campaign was launched in the UK

- Referral patterns
- - Referral is dictated by stage at diagnosis and treatment approach

PATIENT SEGMENTATION
- Stage distribution ?The American Joint Committee on Cancer TNM classification system has replaced the older Dukes' staging system

CURRENT TREATMENT OPTIONS
- Overview of the available drug classes
- Stage I-III ?Treatment type
- - Chemotherapy prescribing trends
- - Chemoradiation prescribing trends

- Stage IV
- - Treatment type
- - Prescribing trends: first line
- - Prescribing trends: second line and third line

- Local and distant relapse
- - Local and distant relapse rates
- - Treatment and prescribing trends: local relapse
- - Treatment and prescribing trends: distant relapse

- Future changes in therapy
- - Targeted therapies and companion diagnostics

BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- Other

APPENDIX A
- Physician data

APPENDIX B
- Contributing experts
- Conferences attended
- Report methodology

TABLES
- Table: Rectal cancer 5-year survival rates by stage at diagnosis, 2001-07
- Table: Leading treatments for rectal cancer across the seven major markets
- Table: Percentage of patients receiving surgery, chemoradiation, and chemotherapy combined, in the seven major markets, 2011
- Table: Survey respondents by country and physician type across the seven major markets, 2011

FIGURES
- Figure: Relative sensitivity and specificity of different colorectal cancer screening tests
- Figure: Distribution of rectal cancer patients across the seven major markets, by stage, 2011
- Figure: Mean percentage of Stage III rectal cancer patients treated by survey respondents in the seven major markets, 2011
- Figure: Percentage of Stage I-III rectal cancer patients receiving each treatment type in the seven major markets, 2011
- Figure: Percentage of Stage II-IIIc patients treated with surgery and chemotherapy receiving chemotherapy neoadjuvantly, adjuvantly, or both in the seven major markets, 2011
- Figure: Top three chemotherapy regimens used in the adjuvant treatment of Stage IIIb rectal cancer in each of the seven major markets, 2011
- Figure: Percentage of Stage II-IIIc patients treated with surgery and chemoradiation receiving chemoradiation neoadjuvantly, adjuvantly, or both in the seven major markets, 2011
- Figure: Top three chemoradiation regimens used in the neoadjuvant treatment of Stage IIIb rectal cancer in each of the seven major markets, 2011
- Figure: Top three treatment types used in Stage IV rectal cancer across the seven major markets, 2011
- Figure: Top three regimens used in the first-line treatment of Stage IV rectal cancer in each of the seven major markets, 2011
- Figure: Percentage of Stage IV patients treated with surgery and chemotherapy receiving chemotherapy neoadjuvantly, adjuvantly, or both, 2011
- Figure: Top three regimens used adjuvantly with surgery for first-line treatment of Stage IV rectal cancer in each of the seven major markets, 2011
- Figure: Number of Stage IV patients receiving additional chemotherapy after first line across the seven major markets, 2011
- Figure: Top three regimens used for second-line treatment of Stage IV rectal cancer in each of the seven major markets, 2011
- Figure: Top three regimens used for third-line treatment of Stage IV rectal cancer in each of the seven major markets, 2011
- Figure: Percentage of Stage I-III rectal cancer patients experiencing local or distant relapse in the seven major markets, 2011
- Figure: Top three chemotherapy regimens used for treatment of local relapse rectal cancer patients in the seven major markets, 2011
- Figure: Top three chemoradiation regimens used for treatment of local relapse rectal cancer patients in the seven major markets, 2011
- Figure: Top three regimens used for treatment of first-line distant relapse rectal cancer patients in the seven major markets, 2011
- Figure: Top three regimens used for the treatment of second-line distant relapse rectal cancer patients in the seven major markets in 2011
- Figure: Top three regimens used for the treatment of third-line distant relapse rectal cancer patients in the seven major markets in 2011
- Figure: Physician opinion regarding the role of companion diagnostics in increasing the uptake of targeted therapies in rectal cancer in the seven major markets, 2011
 
Companies Mentioned
- Merck KGaA
- Schindler Holding Ltd.
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2154142

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Sep 16th 2014
4:50:35 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Treatment Algorithms: Rectal Cancer – Inclusion of Chemoradiation can Influence Treatment and Prescribing Trends

Web Address

http://www.researchandmarkets.com/reports/2154142

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 7,600
Electronic (PDF) - Enterprisewide USD 19,000

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Sep 16th 2014
4:50:35 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)